Erdöl, ŞahinBilgin, HüseyinSağlam, Halil2024-06-272024-06-272021-11-010334-018Xhttps://doi.org/10.1515/jpem-2021-0260https://www.degruyter.com/document/doi/10.1515/jpem-2021-0260/htmlhttps://hdl.handle.net/11452/42488Objectives: We aimed to compare plasmapheresis and medical apheresis as lipid-lowering therapies in children with familial lipoprotein lipase (LPL) deficiency. Methods: The data of 13 patients who were followed up after a diagnosis of LPL deficiency were retrospectively analyzed. Plasma triglyceride, cholesterol, amylase, and lipase values and complications were recorded before and after each patient underwent plasmapheresis or medical apheresis. Results: The mean follow-up period of the patients was 99.64 +/- 52.92 months in the medical apheresis group and 118 +/- 16.97 months in the plasmapheresis group. While the mean triglyceride level before plasmapheresis was 1,875.38 +/- 547.46 mg/dL, it was 617 +/- 228.28 mg/dL after plasmapheresis. While the mean triglyceride level before medical apheresis was 1,756.86 +/- 749.27 mg/dL, it was found to be 623.03 +/- 51.36 mg/dL after medical apheresis. Triglyceride levels were decreased by 59.62% with medical apheresis and 65.57% with plasmapheresis. The cost of treatment for medical apheresis was found to be lower compared to plasmapheresis 296.93 +/- 29.94 Turkish lira (USD 43.34 +/- 4.01) vs. 3,845.42 +/- 156.17 Turkish lira (USD 561.37 +/- 20.93; p<0.001). Conclusions: Although there is no standardized strategy for the acute treatment of hypertriglyceridemia due to LPL deficiency, medical apheresis is a safe and effective treatment with a low risk of side effects. Unlike plasmapheresis, medical apheresis can be performed in any center, which is another important advantage of the procedure. A greater catabolism. diabetes, tions gene the titis, xhantoms acute zil, familial and these there treatment. tingeninfo:eu-repo/semantics/closedAccessLipoprotein-lipasePancreatitisPatientInsulinDeficiencyMutationsTherapyHypertriglyceridemiaInsulinLipoproteinlipase deficiencyMedical apheresisPlasmapheresisScience & technologyLife sciences & biomedicineEndocrinology & metabolismPediatricsArticle00071737340000814191424341110.1515/jpem-2021-02602191-0251